Quantumzyme Research Demonstrates Computational Approach to Sustainable Drug Manufacturing

Quantumzyme Corp. announced the publication of research in the Journal of Molecular Graphics & Modelling describing the company’s application of a fully in silico enzyme engineering approach to biocatalyst design. The peer-reviewed study examines whether enzyme variants can be computationally optimized before experimental testing, specifically focusing on transaminase enzyme variants used in the asymmetric synthesis of L-HPE, a chiral intermediate relevant to certain ACE inhibitor drug manufacturing processes.

The research employed large-scale virtual screening and ranking methodologies to assess enzyme-substrate interactions, catalytic alignment, and structural stability under defined simulation conditions. Rather than relying exclusively on traditional experimental iteration, this approach enabled the identification of enzyme candidates for subsequent experimental consideration. According to Naveen Kulkarni, Chief Executive Officer of Quantumzyme Corp., publishing this research represents an important scientific milestone for the company. ‘This study contributes to the growing body of evidence supporting computational enzyme engineering as a complementary tool in biocatalyst development,’ Kulkarni said.

The study underscores the expanding role of computational modeling in biocatalysis research. By supporting early-stage evaluation and hypothesis testing, in silico methodologies may help reduce experimental iteration and improve the prioritization of enzyme candidates for laboratory study. Quantumzyme focuses on integrating computational modeling with experimental workflows, aiming to improve research efficiency and better inform downstream validation efforts. The full research paper is available at https://www.sciencedirect.com/science/article/pii/S1093326326000343.

While further laboratory validation and scale-up studies are required, the company believes computational biocatalysis represents an important component of future sustainable pharmaceutical manufacturing strategies. The publication does not represent regulatory approval, commercial validation, or confirmation of manufacturing readiness. Additional experimental testing, optimization, and scale-up would be required before any potential industrial application. The company also announced that the Financial Industry Regulatory Authority has received all information necessary to complete its review of the company’s previously announced corporate name change and corresponding trading symbol request.

Based on current communications, the company understands that FINRA’s review process is progressing and anticipates that, subject to FINRA’s final approval, the name change and new trading symbol are expected in the coming days. Regulatory processes remain outside of the company’s control, and no assurance can be given regarding the exact timing or approval of the request. Upon effectiveness, the company intends to issue a separate announcement confirming the official name and ticker symbol change. For more information, visit https://www.quantumzymecorp.com and the company’s profile at https://www.otcmarkets.com/stock/QTZM.

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Quantumzyme Research Demonstrates Computational Approach to Sustainable Drug Manufacturing.

The post Quantumzyme Research Demonstrates Computational Approach to Sustainable Drug Manufacturing appeared first on citybuzz.